Pay in 4 interest-free payments of $6.97 Learn more
Ships within 48 hours · Estimated delivery Aug 21 - Aug 26
Clinical Update
Clinical trial data from the SURMOUNT and SURPASS programs showed tirzepatide patients losing an average of 20 to 25 percent of body weight at the highest doses, compared to roughly 15 to 17 percent for semaglutide in similar trials
The interest in tendon recovery is backed by preclinical work such as this study examining how BPC-157 influences tendon fibroblast healing and growth factor expression in injured connective tissue
10.1038/s41419-024-07244-x Cell Death Dis
US$ 24.74
US$ 27.77
US$ 22.90
